Previous close | 2,822.00 |
Open | 2,828.00 |
Bid | 2,847.50 x 0 |
Ask | 2,847.00 x 0 |
Day's range | 2,812.00 - 2,848.98 |
52-week range | 2,422.50 - 3,308.50 |
Volume | 145,111 |
Avg. volume | 4,588,187 |
Market cap | 65.35B |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | 10.21 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.16 (7.64%) |
Ex-dividend date | 08 Jul 2021 |
1y target est | N/A |
OrganiGram Holdings (NASDAQ: OGI) reported its fiscal second-quarter 2021 results this morning, and the stock initially dropped 12% on the report. The decline quickly eased, however, with shares trading about 2% lower than Monday's close as of 10:20 a.m. EDT. OrganiGram CEO Greg Engel noted the business was "challenged by industry dynamics, COVID-19 and staffing limitations at our facility."
Shareholders of tobacco giant British American Tobacco (NYSE: BTI) had to be happy with the month of March, as shares gained 11.6% in the period, according to data provided by S&P Global Market Intelligence. In mid-February, when the company reported its fiscal 2020 results, BAT updated investors on several aspects of its "new categories" segment. Its Vuse vapor revenue grew 85%, for example.
The stocks of several cannabis producers have more than doubled just since the start of the year, including Organigram Holdings (NASDAQ: OGI). Organigram got an added boost from news of a strategic partnership in March, helping its shares gain 14.5% in the month, according to data provided by S&P Global Market Intelligence. On March 11, news that Organigram and tobacco giant British American Tobacco (NYSE: BTI) formed a business alliance caused the stock to spike almost 40% that day.